Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.

Ther Adv Med Oncol · 2021 · PMC8606735 · PMID 34819998

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, our data showed a trend toward lower objective tumor responses and disease control rates among patients who received lower pre-emptive nal-IRI dosing.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.